Latest news with #WenzhouYihuaConnector
Yahoo
a day ago
- Business
- Yahoo
Asian Stocks That Investors Might Be Undervaluing
As global markets navigate a landscape marked by trade tensions and economic shifts, Asian stocks are drawing attention amid hopes for governmental stimulus and evolving geopolitical dynamics. In this environment, identifying undervalued stocks can be key, as investors look for opportunities where market perceptions may not fully reflect potential value. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.24 CN¥76.36 49.9% Wanguo Gold Group (SEHK:3939) HK$30.70 HK$61.36 50% Lucky Harvest (SZSE:002965) CN¥41.05 CN¥81.83 49.8% Livero (TSE:9245) ¥1700.00 ¥3349.85 49.3% Kanto Denka Kogyo (TSE:4047) ¥838.00 ¥1673.94 49.9% IG Port (TSE:3791) ¥1844.00 ¥3631.34 49.2% Food & Life Companies (TSE:3563) ¥6515.00 ¥13024.46 50% Ficont Industry (Beijing) (SHSE:605305) CN¥26.52 CN¥52.32 49.3% Elan (TSE:6099) ¥851.00 ¥1698.32 49.9% Brangista (TSE:6176) ¥596.00 ¥1181.09 49.5% Click here to see the full list of 294 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's review some notable picks from our screened stocks. Overview: DigiPlus Interactive Corp., with a market cap of ₱272.12 billion, operates as a digital entertainment company in the Philippines through its subsidiaries. Operations: The company's revenue segments include the Retail Group with ₱83.81 billion, the Casino Group with ₱503.77 million, and the Network and License Group with ₱414.68 million. Estimated Discount To Fair Value: 30.8% DigiPlus Interactive is trading at ₱61.1, significantly below its estimated fair value of ₱88.33, suggesting it is undervalued based on cash flows. The company reported strong earnings growth with net income rising to ₱4.20 billion in Q1 2025 from ₱2 billion a year ago and forecasts indicate continued high earnings growth of over 23% annually, outpacing the Philippine market. Recent international expansion efforts further position DigiPlus for sustained revenue increases and strategic global partnerships. Insights from our recent growth report point to a promising forecast for DigiPlus Interactive's business outlook. Click here to discover the nuances of DigiPlus Interactive with our detailed financial health report. Overview: Zhejiang China Commodities City Group Co., Ltd. develops, manages, and operates an online trading platform in China with a market cap of CN¥101.34 billion. Operations: The company's revenue segments include the development, management, and operation of a service online trading platform in China. Estimated Discount To Fair Value: 26.6% Zhejiang China Commodities City Group is trading at CN¥18.48, below its estimated fair value of CN¥25.18, highlighting potential undervaluation based on cash flows. Recent results show robust financial performance with Q1 2025 sales reaching CN¥3.16 billion, up from CN¥2.68 billion a year ago, and net income rising to CN¥803.32 million from CN¥713.02 million. Earnings are projected to grow significantly at 27% annually over the next three years, outpacing the Chinese market growth rate. Our comprehensive growth report raises the possibility that Zhejiang China Commodities City Group is poised for substantial financial growth. Take a closer look at Zhejiang China Commodities City Group's balance sheet health here in our report. Overview: Taiwan Union Technology Corporation manufactures and sells copper foil substrates, adhesive sheets, and multi-layer laminated boards both in Taiwan and internationally, with a market capitalization of NT$59.94 billion. Operations: The company's revenue segments include copper foil substrates at NT$7.50 billion, adhesive sheets at NT$3.20 billion, and multi-layer laminated boards at NT$5.80 billion. Estimated Discount To Fair Value: 48.8% Taiwan Union Technology, trading at NT$217, is significantly undervalued with a fair value estimate of NT$423.55. Recent Q1 2025 results show strong performance, with sales rising to NT$6.37 billion from NT$4.43 billion and net income increasing to NT$671.95 million from NT$451.84 million year-on-year. Despite high volatility in its share price recently, earnings are expected to grow substantially at over 20% annually for the next three years, exceeding Taiwan's market growth rate. Upon reviewing our latest growth report, Taiwan Union Technology's projected financial performance appears quite optimistic. Navigate through the intricacies of Taiwan Union Technology with our comprehensive financial health report here. Click here to access our complete index of 294 Undervalued Asian Stocks Based On Cash Flows. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PSE:PLUS SHSE:600415 and TPEX:6274. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Asian Value Stocks Estimated Below Intrinsic Worth
As global markets navigate a complex landscape, the Asian financial scene is drawing attention with its potential for value investing, particularly as China's economic indicators suggest room for further stimulus and Japan's moderate recovery continues. In this environment, identifying stocks that are trading below their intrinsic worth can be an effective strategy, offering opportunities to capitalize on market inefficiencies while mitigating risk through thorough analysis. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Yuhan Corporation is a South Korean company that manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both domestically and internationally, with a market cap of ₩8.04 trillion. Operations: The company's revenue segments include biotechnology startups, which contribute ₩2.11 billion to its overall earnings. Estimated Discount To Fair Value: 22.4% Yuhan's current trading price of ₩107,300 is significantly below its estimated fair value of ₩138,269.28, suggesting it may be undervalued based on cash flows. Despite a forecasted 44% annual earnings growth outpacing the Korean market average, recent financials show declining profit margins and net income compared to the previous year. The company has engaged in substantial share buybacks over time but reported no repurchases in early 2025. Our comprehensive growth report raises the possibility that Yuhan is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Yuhan. Overview: ASMPT Limited is an investment holding company that designs, manufactures, and markets machines, tools, and materials for the semiconductor and electronics assembly industries globally, with a market cap of HK$23.74 billion. Operations: The company's revenue is primarily derived from its Semiconductor Solutions segment, which generated HK$7.42 billion, and its Surface Mount Technology (SMT) Solutions segment, contributing HK$5.79 billion. Estimated Discount To Fair Value: 41.9% ASMPT's current trading price of HK$57 is significantly below its estimated fair value of HK$98.04, highlighting potential undervaluation based on cash flows. Despite a decrease in profit margins and net income compared to the previous year, ASMPT anticipates revenue growth between US$410 million and US$470 million for Q2 2025, driven by seasonal factors and strong bookings. The company declared a special dividend of HKD 0.25 per share but reduced its final dividend to HKD 0.07 per share for 2024. The analysis detailed in our ASMPT growth report hints at robust future financial performance. Get an in-depth perspective on ASMPT's balance sheet by reading our health report here. Overview: Accton Technology Corporation is engaged in the research, development, manufacturing, and sale of network communication equipment across Taiwan, America, Asia, Europe, and other international markets with a market cap of NT$411.92 billion. Operations: The company's revenue primarily comes from its Computer Networks segment, which generated NT$134.33 billion. Estimated Discount To Fair Value: 33.9% Accton Technology's current trading price of NT$737 is substantially below its estimated fair value of NT$1115.68, suggesting undervaluation based on cash flows. The company reported significant earnings growth for Q1 2025, with net income rising to TWD 5.13 billion from TWD 2.24 billion a year earlier. Despite high non-cash earnings, Accton's projected revenue and profit growth rates exceed Taiwan's market averages, indicating robust future performance potential despite moderate annual profit growth forecasts. Our earnings growth report unveils the potential for significant increases in Accton Technology's future results. Click to explore a detailed breakdown of our findings in Accton Technology's balance sheet health report. Access the full spectrum of 302 Undervalued Asian Stocks Based On Cash Flows by clicking on this link. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A000100 SEHK:522 and TWSE:2345. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Asian Value Stocks Estimated Below Intrinsic Worth
As global markets navigate a complex landscape, the Asian financial scene is drawing attention with its potential for value investing, particularly as China's economic indicators suggest room for further stimulus and Japan's moderate recovery continues. In this environment, identifying stocks that are trading below their intrinsic worth can be an effective strategy, offering opportunities to capitalize on market inefficiencies while mitigating risk through thorough analysis. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Yuhan Corporation is a South Korean company that manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both domestically and internationally, with a market cap of ₩8.04 trillion. Operations: The company's revenue segments include biotechnology startups, which contribute ₩2.11 billion to its overall earnings. Estimated Discount To Fair Value: 22.4% Yuhan's current trading price of ₩107,300 is significantly below its estimated fair value of ₩138,269.28, suggesting it may be undervalued based on cash flows. Despite a forecasted 44% annual earnings growth outpacing the Korean market average, recent financials show declining profit margins and net income compared to the previous year. The company has engaged in substantial share buybacks over time but reported no repurchases in early 2025. Our comprehensive growth report raises the possibility that Yuhan is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Yuhan. Overview: ASMPT Limited is an investment holding company that designs, manufactures, and markets machines, tools, and materials for the semiconductor and electronics assembly industries globally, with a market cap of HK$23.74 billion. Operations: The company's revenue is primarily derived from its Semiconductor Solutions segment, which generated HK$7.42 billion, and its Surface Mount Technology (SMT) Solutions segment, contributing HK$5.79 billion. Estimated Discount To Fair Value: 41.9% ASMPT's current trading price of HK$57 is significantly below its estimated fair value of HK$98.04, highlighting potential undervaluation based on cash flows. Despite a decrease in profit margins and net income compared to the previous year, ASMPT anticipates revenue growth between US$410 million and US$470 million for Q2 2025, driven by seasonal factors and strong bookings. The company declared a special dividend of HKD 0.25 per share but reduced its final dividend to HKD 0.07 per share for 2024. The analysis detailed in our ASMPT growth report hints at robust future financial performance. Get an in-depth perspective on ASMPT's balance sheet by reading our health report here. Overview: Accton Technology Corporation is engaged in the research, development, manufacturing, and sale of network communication equipment across Taiwan, America, Asia, Europe, and other international markets with a market cap of NT$411.92 billion. Operations: The company's revenue primarily comes from its Computer Networks segment, which generated NT$134.33 billion. Estimated Discount To Fair Value: 33.9% Accton Technology's current trading price of NT$737 is substantially below its estimated fair value of NT$1115.68, suggesting undervaluation based on cash flows. The company reported significant earnings growth for Q1 2025, with net income rising to TWD 5.13 billion from TWD 2.24 billion a year earlier. Despite high non-cash earnings, Accton's projected revenue and profit growth rates exceed Taiwan's market averages, indicating robust future performance potential despite moderate annual profit growth forecasts. Our earnings growth report unveils the potential for significant increases in Accton Technology's future results. Click to explore a detailed breakdown of our findings in Accton Technology's balance sheet health report. Access the full spectrum of 302 Undervalued Asian Stocks Based On Cash Flows by clicking on this link. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A000100 SEHK:522 and TWSE:2345. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
3 days ago
- Business
- Yahoo
June 2025's Asian Stock Picks Estimated Below Fair Value
As global markets navigate a complex landscape marked by trade tensions and economic shifts, Asian markets have shown resilience, with Chinese stocks gaining ground amid expectations of government stimulus. In this environment, identifying undervalued stocks can be a strategic approach for investors seeking opportunities below fair value, especially when considering factors such as market sentiment and macroeconomic developments. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: BYD Company Limited, along with its subsidiaries, operates in the automobiles and batteries sectors across China, Hong Kong, Macau, Taiwan, and internationally, with a market cap of approximately HK$1.17 trillion. Operations: BYD's revenue is primarily derived from its operations in the automobiles and batteries sectors, serving markets in China, Hong Kong, Macau, Taiwan, and internationally. Estimated Discount To Fair Value: 28.2% BYD is trading at HK$132.2, significantly below its estimated fair value of HK$184.06, indicating potential undervaluation based on cash flows. The company has demonstrated robust earnings growth of 47.2% over the past year and anticipates future revenue growth of 13.2% annually, outpacing the Hong Kong market average. Recent developments include a substantial dividend payout approved at their AGM and expansion plans in Europe, which could further enhance BYD's financial performance and market position in the EV sector. Upon reviewing our latest growth report, BYD's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of BYD stock in this financial health report. Overview: Everest Medicines Limited is a biopharmaceutical company focused on discovering, licensing, developing, and commercializing therapies and vaccines for critical unmet medical needs in Greater China and other Asia Pacific markets, with a market cap of HK$17.70 billion. Operations: The company's revenue segment includes Pharmaceuticals, generating CN¥706.68 million. Estimated Discount To Fair Value: 49% Everest Medicines is trading at HK$54.55, significantly below its estimated fair value of HK$107.01, suggesting potential undervaluation based on cash flows. The company anticipates a robust revenue growth rate of 29.8% annually, surpassing the Hong Kong market average. Recent product approvals for NEFECON in China and positive trial results for EVER001 underscore its strategic advancements in nephrology treatments, though profitability challenges remain with a net loss reported at CNY 1.04 billion last year. In light of our recent growth report, it seems possible that Everest Medicines' financial performance will exceed current levels. Click to explore a detailed breakdown of our findings in Everest Medicines' balance sheet health report. Overview: Bosideng International Holdings Limited operates in the apparel business in the People's Republic of China, with a market cap of HK$51.78 billion. Operations: The company's revenue segments include Down Apparels generating CN¥20.66 billion, Ladieswear Apparels contributing CN¥735.22 million, Diversified Apparels at CN¥254.12 million, and Original Equipment Manufacturing (OEM) Management bringing in CN¥2.97 billion. Estimated Discount To Fair Value: 23.2% Bosideng International Holdings is trading at HK$4.52, below its estimated fair value of HK$5.89, highlighting potential undervaluation based on cash flows. The company's earnings grew by 41.4% last year and are projected to grow 12.92% annually, outpacing the Hong Kong market's average growth rate of 10.4%. Despite an unstable dividend track record, analysts agree the stock price could rise by 23.6%, with revenue growth forecasted at 10.9% per year. Our earnings growth report unveils the potential for significant increases in Bosideng International Holdings' future results. Delve into the full analysis health report here for a deeper understanding of Bosideng International Holdings. Dive into all 302 of the Undervalued Asian Stocks Based On Cash Flows we have identified here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1211 SEHK:1952 and SEHK:3998. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
3 Asian Stocks Estimated To Be Trading Below Intrinsic Value By Up To 27.8%
Amidst the complex interplay of trade policies and economic strategies, Asian markets have experienced varied performances, with some regions showing resilience while others face challenges. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. Understanding what makes a stock potentially undervalued involves assessing its financial health, growth prospects, and market position relative to current economic conditions. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥39.04 CN¥76.73 49.1% MicroPort CardioFlow Medtech (SEHK:2160) HK$0.88 HK$1.75 49.7% Livero (TSE:9245) ¥1701.00 ¥3361.77 49.4% Kanto Denka Kogyo (TSE:4047) ¥843.00 ¥1677.35 49.7% J&T Global Express (SEHK:1519) HK$6.77 HK$13.35 49.3% Good Will Instrument (TWSE:2423) NT$43.80 NT$87.36 49.9% GEM (SZSE:002340) CN¥6.11 CN¥12.00 49.1% Ficont Industry (Beijing) (SHSE:605305) CN¥26.63 CN¥52.45 49.2% cottaLTD (TSE:3359) ¥430.00 ¥858.34 49.9% BalnibarbiLtd (TSE:3418) ¥1165.00 ¥2295.31 49.2% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: MicroPort NeuroScientific Corporation focuses on the research, development, production, and sale of neuro-interventional medical devices in China and internationally, with a market cap of HK$7.06 billion. Operations: The company generates revenue of CN¥761.76 million from its Surgical & Medical Equipment segment. Estimated Discount To Fair Value: 18.1% MicroPort NeuroScientific appears undervalued based on cash flows, trading at HK$12.26 below its fair value estimate of HK$14.97. Its earnings grew by 74.6% last year, with future earnings expected to grow significantly at 21.5% annually, surpassing the Hong Kong market's growth rate of 10.4%. Recent financials show net income increased to CNY 254.17 million from CNY 145.55 million, reflecting robust profitability despite a forecasted low return on equity of 17.3%. Our comprehensive growth report raises the possibility that MicroPort NeuroScientific is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of MicroPort NeuroScientific. Overview: Auras Technology Co., Ltd. is involved in the manufacturing, processing, and retailing of electronic materials and computer cooling modules across various international markets, with a market cap of NT$54.89 billion. Operations: The company generates revenue of NT$17.04 billion from its Electronic Components & Parts segment. Estimated Discount To Fair Value: 27.8% Auras Technology is trading at TWD 608, significantly below its estimated fair value of TWD 841.98, highlighting its undervaluation based on cash flows. The company reported strong earnings growth of 48.7% last year and forecasts suggest continued robust profit growth at 25.5% annually, outpacing the Taiwan market's average. Despite recent share price volatility, Auras maintains a high return on equity forecast of 30.4%, with revenue expected to grow by 21.8% annually over the next three years. Our earnings growth report unveils the potential for significant increases in Auras Technology's future results. Unlock comprehensive insights into our analysis of Auras Technology stock in this financial health report. Overview: Rakus Co., Ltd., along with its subsidiaries, offers cloud services in Japan and has a market cap of ¥411.24 billion. Operations: The company's revenue segments include the Cloud Business, generating ¥41.86 billion, and the IT Outsourcing Business, contributing ¥7.06 billion. Estimated Discount To Fair Value: 22.4% Rakus is trading at ¥2,281, which is 22.4% below its estimated fair value of ¥2,940.11, underscoring its undervaluation based on cash flows. The company has demonstrated strong earnings growth of 91.2% over the past year and forecasts suggest continued robust profit growth at 23.6% annually, surpassing the JP market's average. Recent share buybacks totaling ¥1,999.85 million aim to enhance capital efficiency and return profits to shareholders. In light of our recent growth report, it seems possible that Rakus' financial performance will exceed current levels. Dive into the specifics of Rakus here with our thorough financial health report. Delve into our full catalog of 302 Undervalued Asian Stocks Based On Cash Flows here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2172 TPEX:3324 and TSE:3923. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
